Filament Health Corp. (FH.NE) (“Filament”) announced today that it will be participating in three conferences throughout December 2021. These conferences include the Horizons: Perspectives on Psychedelics Conference, H.C. Wainwright 2nd Annual Psychedelics Conference, and the GCI Summit Psychedelics Conference.

The Horizons: Perspectives on Psychedelics Conference (“Horizon”) is an annual conference intended to assist the public in understanding psychedelics. The conference features live and digital forums, classes, and films that examine the role of psychedelic drugs and plant medicines in science, medicine, culture, and spirituality. It is worth noting that Horizon is the largest and longest-running annual gathering of the psychedelics community in the world.

Horizon will be held virtually and live in New York City for December 1-5, 2021, marking the conference’s 14th anniversary. Filament’s CEO, Benjamin Lightburn, will be attending the conference on December 2, 2021.

The H.C. Wainwright 2nd Annual Psychedelics Conference (“Wainwright”) features a variety of beneficial events for both companies and investors alike. For example, Wainwright offers 1-on-1 investor meetings, allowing investors to communicate directly with company executives. Additionally, networking opportunities are available through the H.C. Wainwright Investment Banking & Research Teams, which will be present at the conference. As you’d expect from any conference, a variety of companies will also be presenting their latest news and updates, including Filament.

The Wainwright conference will be held virtually on December 6, 2021. An on-demand presentation featuring Mr. Lightburn will be available beginning at 7:00 AM EST on December 6, 2021.

Lastly, the GCI Summit Psychedelics Conference (“GCI Summit”) brings together global leaders across each sector of cannabis and psychedelics. At the GCI Summit, attendees are able to participate in talk and network with leaders most relevant to their needs. The conference offers a Content Hub, a free service offering articles, interviews, videos, and audio submitted by global leaders operating across the cannabis industry’s value chain.

The GCI Summit will also be held virtually on December 7-9, 2021. Mr. Lightburn will be presenting alongside Ryan Moss, the Company’s Director of Research, and Dr. Joshua Woolley, Director of the Translational Psychedelic Research Program (TrPR) at the University of California, San Francisco. The group will be presenting on December 8, 2021, at 1:00 PM EST, with the session available on-demand post-broadcast.

Why Should You Care?

An estimated 26% of Americans ages 18 and older, or roughly 1 in 4 adults, suffer from a diagnosable mental disorder in a given year. Each year, approximately 9.5% of American adults ages 18 and over, will suffer from a depressive illness, such as major depression, bipolar disorder, or dysthymia. With this in mind, mental disorders are a worldwide crisis affecting millions worldwide.

In fact, following the onset of COVID-19, health care workers reported feelings of anxiety and depression as well as thoughts of suicide. According to the KFF Health Tracking Poll conducted in the middle of April 2020, 64% of households with a health care worker said stress over the coronavirus caused them to experience at least one adverse impact on their mental health such as increased alcohol consumption, increased eating, or trouble sleeping.

With this in mind, psychedelics have been studied for their therapeutic potential, demonstrating efficacy for treating depression, post-traumatic stress disorder (PTSD), anxiety disorders, and substance abuse disorder, to name just a few. As a result, the Psychedelic Drug Market has grown substantially and is expected to continue expanding at a compound annual growth rate (CAGR) of 14.5%. By 2026, this market is expected to reach a value of $6.33 billion, up from $3.21 billion in 2021.